

# CITATION REPORT

List of articles citing

Safety and pharmacokinetics of a new biosimilar trastuzumab (HLO2): a Phase I bioequivalence study in healthy Chinese men

DOI: 10.1080/14712598.2021.1894121

Expert Opinion on Biological Therapy, 2021, , 1-8.

**Source:** <https://exaly.com/paper-pdf/79329358/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Pharmacokinetics, Immunogenicity and Safety Study for SHR-1309 Injection and Perjeta <sup>®</sup> in Healthy Chinese Male Volunteers. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 660541	5.6	0
4	A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects.. <i>Investigational New Drugs</i> , <b>2022</b> , 1	4.3	0
3	HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.. <i>BioDrugs</i> , <b>2022</b> ,	7.9	1
2	Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. <b>2022</b> , 10, 2045		0
1	A Randomized, Single-dose, Phase I Clinical Comparison of a Trastuzumab Biosimilar With a Reference Trastuzumab Formulation in Healthy Chinese Male Volunteers.		0